A month after Biogen signaled plans to shift its attention to “ external opportunities ,” it delivered on that ...
Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug ...
The federal government said it 'ran afoul of no statute' when it announced a 15% cap on indirect cost reimbursements for NIH ...
Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move ...
Siegfried’s stock dipped by 6% on the Swiss stock exchange Tuesday after reporting a lower-than-expected sales forecast for ...
Subsense, a startup building noninvasive technology to communicate with the brain, is launching with $17 million in funding.
A biotech based in Vilnius, Lithuania has won the backing of Lux Capital as the startup plots a US expansion in 2025. Lux led ...
Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will ...
Septerna halts Phase 1 trial of SEP-786 for hypoparathyroidism due to safety concerns, FDA approves Sanofi's Merilog insulin biosimilar, plus updates from Basilea and TME Pharma ...
The former head of the FDA on Tuesday criticized the Trump administration’s efforts to lay off recently hired employees who review the safety of medical devices and other products.
Trump administration establishes Make America Healthy Again commission, fires HHS workers including FDA/CMS staff. FDA AI division hit by cuts.
FDA approves Ono Pharmaceutical's Romvimza for TGCT, meaning it will compete with Daiichi Sankyo's Turalio. Drug shows better safety profile and twice-weekly dosing vs twice-daily Turalio.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback